GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » RP Bio lnc (XKRX:314140) » Definitions » Piotroski F-Score

RP Bio lnc (XKRX:314140) Piotroski F-Score : 5 (As of May. 14, 2024)


View and export this data going back to 2022. Start your Free Trial

What is RP Bio lnc Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

RP Bio lnc has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for RP Bio lnc's Piotroski F-Score or its related term are showing as below:

XKRX:314140' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 5   Max: 5
Current: 5

During the past 4 years, the highest Piotroski F-Score of RP Bio lnc was 5. The lowest was 5. And the median was 5.


RP Bio lnc Piotroski F-Score Historical Data

The historical data trend for RP Bio lnc's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RP Bio lnc Piotroski F-Score Chart

RP Bio lnc Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Piotroski F-Score
N/A N/A N/A N/A

RP Bio lnc Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A 5.00

Competitive Comparison of RP Bio lnc's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, RP Bio lnc's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RP Bio lnc's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, RP Bio lnc's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where RP Bio lnc's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 550.15 + 2101.998 + 3250.689 + -465.584 = ₩5,437 Mil.
Cash Flow from Operations was -1660.388 + 1096.961 + 6443.25 + 4700.187 = ₩10,580 Mil.
Revenue was 35504.579 + 38481.356 + 41488.8 + 35571.748 = ₩151,046 Mil.
Gross Profit was 2605.407 + 5253.877 + 5585.419 + 2124.563 = ₩15,569 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(173157.918 + 172021.398 + 173947.958 + 175963.555 + 166217.714) / 5 = ₩172261.7086 Mil.
Total Assets at the begining of this year (Dec22) was ₩173,158 Mil.
Long-Term Debt & Capital Lease Obligation was ₩4,774 Mil.
Total Current Assets was ₩67,714 Mil.
Total Current Liabilities was ₩57,496 Mil.
Net Income was 2779.076 + 3262.473 + 1666.063 + -3391.962 = ₩4,316 Mil.

Revenue was 32399.879 + 35670.785 + 36263.694 + 33774.961 = ₩138,109 Mil.
Gross Profit was 5037.315 + 5458.688 + 4254.654 + 3028.646 = ₩17,779 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(143736.979 + 0 + 155176.92 + 171733.078 + 173157.918) / 5 = ₩160951.22375 Mil.
Total Assets at the begining of last year (Dec21) was ₩143,737 Mil.
Long-Term Debt & Capital Lease Obligation was ₩2,635 Mil.
Total Current Assets was ₩81,043 Mil.
Total Current Liabilities was ₩78,630 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

RP Bio lnc's current Net Income (TTM) was 5,437. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

RP Bio lnc's current Cash Flow from Operations (TTM) was 10,580. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=5437.253/173157.918
=0.03140055

ROA (Last Year)=Net Income/Total Assets (Dec21)
=4315.65/143736.979
=0.03002463

RP Bio lnc's return on assets of this year was 0.03140055. RP Bio lnc's return on assets of last year was 0.03002463. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

RP Bio lnc's current Net Income (TTM) was 5,437. RP Bio lnc's current Cash Flow from Operations (TTM) was 10,580. ==> 10,580 > 5,437 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=4774.218/172261.7086
=0.02771491

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=2634.805/160951.22375
=0.01637021

RP Bio lnc's gearing of this year was 0.02771491. RP Bio lnc's gearing of last year was 0.01637021. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=67713.989/57496.318
=1.17771001

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=81043.298/78630.257
=1.03068845

RP Bio lnc's current ratio of this year was 1.17771001. RP Bio lnc's current ratio of last year was 1.03068845. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

RP Bio lnc's number of shares in issue this year was 11.404. RP Bio lnc's number of shares in issue last year was 8.232. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=15569.266/151046.483
=0.10307599

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=17779.303/138109.319
=0.12873355

RP Bio lnc's gross margin of this year was 0.10307599. RP Bio lnc's gross margin of last year was 0.12873355. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=151046.483/173157.918
=0.8723048

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=138109.319/143736.979
=0.96084751

RP Bio lnc's asset turnover of this year was 0.8723048. RP Bio lnc's asset turnover of last year was 0.96084751. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+1+0+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

RP Bio lnc has an F-score of 5 indicating the company's financial situation is typical for a stable company.

RP Bio lnc  (XKRX:314140) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


RP Bio lnc Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of RP Bio lnc's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


RP Bio lnc (XKRX:314140) Business Description

Traded in Other Exchanges
N/A
Address
634, Samseong-ro, Gangnam-gu, Seoul, KOR, 06084
RP Bio lnc is engaged in the pharmaceutical manufacturing business. It produces softgels, finished drugs, and other products.

RP Bio lnc (XKRX:314140) Headlines

No Headlines